Increasing evidence now suggests that tyrosine kinase inhibitors (TKIs) improves progression-free survival in patients with metastatic NSCLC harboring EGFR mutations or ALK rearrangement (7, 64). The gene discussed is ALK; the disease is non-small cell lung carcinoma.